TECARTUS 0.4 - 2 x 100 000 000 cells, dispersion for infusion bag, 68 ml
Active ingredients: CELLULES AUTOLOGUES CD3+ TRANSDUITES ANTI-CD19
Commercialized according to BDPMDispensing in France: Prescription only, hospital use
Dispersion for infusionbag, 68 mlintraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- TECARTUS 0,4 - 2 x 100 000 000 cellules, dispersion pour perfusion
- Pharmaceutical form
- dispersion pour perfusion
- Route of administration
- intraveineuse
- Presentation description
- 1 poche de cryoconservation EVA : éthylène vinyl acétate copolymère de 68 ml comprenant un tube d'alimentation flexible scellé et deux dispositifs de perfusion
- Marketing authorisation holder
- KITE PHARMA EU (PAYS-BAS)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 1 Apr 2021
- Prescription and dispensing conditions
- Prescription only, hospital use
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by specialists only
- Hospital use only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
60862404CIP75507720CIP133400955077206Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CELLULES AUTOLOGUES CD3+ TRANSDUITES ANTI-CD19dispersion | 2 x 100 000 000 cellules au maximum · une poche | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.